Piramal Pharma posts INR 88.2 mln loss in Jan-Mar, fails to beat Street view
This story was originally published at 09:13 IST on 29 April 2026
Register to read our real-time news.Informist, Wednesday, Apr. 29, 2026
Please click here to read all liners published on this story
--Piramal Pharma Jan-Mar consol net loss INR 88.2 mln
--Analysts saw Piramal Pharma Jan-Mar consol PAT INR 1.46 bln
--Piramal Pharma Jan-Mar consol revenue INR 27.52 bln
--Analysts saw Piramal Pharma Jan-Mar consol revenue INR 26.49 bln
--Piramal Pharma Q4 consol net loss INR 88.2 mln vs INR 1.54 bln PAT yr ago
--Piramal Pharma Jan-Mar consol revenue INR 27.52 bln vs INR 27.54 bln yr ago
--Piramal Pharma Q4 net loss includes one-time cost INR 1.76 bln
--Piramal Pharma reappoints Nandini Piramal as executive director,chairperson
--Piramal Pharma FY26 consol net loss INR 3.3 bln vs INR 911.3 mln PAT yr ago
--Piramal Pharma FY26 consol revenue INR 88.69 bln vs INR 91.51 bln yr ago
MUMBAI – Piramal Pharma Ltd. reported a consolidated loss of INR 88.2 million for the March quarter compared to a net profit of INR 1.54 billion a year ago. The bottom line failed to beat analysts' estimate of a net profit of INR 1.46 billion by a huge margin. On a sequential basis, its losses narrowed against a loss of INR 1.36 billion in the December quarter. The top line of the company grew marginally on year to INR 27.52 billion.
Piramal Pharma incurred a one-time cost of INR 1.76 billion in the reporting quarter. The one-time loss is an impairment charge pertaining to a certain intangible asset under development in the company. The total income of the company rose marginally on year to INR 27.98 billion. Meanwhile, total expenses rose 2% to INR 25.93 billion. Of this, the cost of raw materials more than doubled on year to INR 4.83 billion. Costs related to change in inventories of finished goods, work-in-progress and stock-in-trade rose nearly 16% on year to INR 2.37 billion.
Earnings before interest, tax, depreciation, and amortisation of the company fell 16% on year to INR 5.07 billion in Jan-Mar. The company reported an EBITDA margin of 18% against 22% reported in the year-ago quarter. For 2025-26 (Apr-Mar), the company reported a net loss of INR 3.3 billion against a net profit of INR 911.3 million in FY25. Revenues of the company fell 3% on year to INR 88.69 billion for the period.
The company appointed Nandini Piramal as the executive director and chairperson of the company for a period of three years. On Tuesday, shares of the company ended nearly 3% lower at INR 164.47 on the National Stock Exchange. End
Reported by Adhithya Aji
Edited by Tanima Banerjee
For users of real-time market data terminals, Informist news is available exclusively on the NSE Cogencis WorkStation.
Cogencis news is now Informist news. This follows the acquisition of Cogencis Information Services Ltd. by NSE Data & Analytics Ltd., a 100% subsidiary of the National Stock Exchange of India Ltd. As a part of the transaction, the news department of Cogencis has been sold to Informist Media Pvt. Ltd.
Informist Media Tel +91 (22) 6985-4000 /+91 (11) 4220-1000
Send comments to feedback@informistmedia.com
© Informist Media Pvt. Ltd. 2026. All rights reserved.
To read more please subscribe
Share this Story:
